Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 an… Read more
Market Cap & Net Worth: Yifan Xinfu Pharmaceutical Co Ltd (002019)
Yifan Xinfu Pharmaceutical Co Ltd (SHE:002019) has a market capitalization of $2.37 Billion (CN¥17.42 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #7185 globally and #1198 in its home market, demonstrating a 7.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yifan Xinfu Pharmaceutical Co Ltd's stock price CN¥14.32 by its total outstanding shares 1216390085 (1.22 Billion).
Yifan Xinfu Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Yifan Xinfu Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $2.49 Billion to $2.37 Billion (3.02% CAGR).
Yifan Xinfu Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yifan Xinfu Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.34x
Yifan Xinfu Pharmaceutical Co Ltd's market cap is 0.34 times its annual revenue
0.92x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
4.60x
Yifan Xinfu Pharmaceutical Co Ltd's market cap is 4.60 times its annual earnings
15.64x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.49 Billion | $2.43 Billion | $360.57 Million | 1.02x | 6.90x |
| 2016 | $2.38 Billion | $3.50 Billion | $704.76 Million | 0.68x | 3.38x |
| 2017 | $3.49 Billion | $4.37 Billion | $1.31 Billion | 0.80x | 2.67x |
| 2018 | $1.73 Billion | $4.63 Billion | $737.44 Million | 0.37x | 2.35x |
| 2019 | $2.65 Billion | $5.19 Billion | $903.47 Million | 0.51x | 2.93x |
| 2020 | $3.10 Billion | $5.40 Billion | $968.39 Million | 0.57x | 3.20x |
| 2021 | $2.89 Billion | $4.41 Billion | $278.40 Million | 0.66x | 10.39x |
| 2022 | $2.01 Billion | $3.84 Billion | $191.22 Million | 0.52x | 10.52x |
| 2023 | $2.43 Billion | $4.07 Billion | -$551.07 Million | 0.60x | N/A |
| 2024 | $1.78 Billion | $5.16 Billion | $385.97 Million | 0.34x | 4.60x |
Competitor Companies of 002019 by Market Capitalization
Companies near Yifan Xinfu Pharmaceutical Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Yifan Xinfu Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Yifan Xinfu Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Yifan Xinfu Pharmaceutical Co Ltd's market cap moved from $2.49 Billion to $ 2.37 Billion, with a yearly change of 3.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.37 Billion | +19.73% |
| 2025 | CN¥1.98 Billion | +11.57% |
| 2024 | CN¥1.78 Billion | -26.77% |
| 2023 | CN¥2.43 Billion | +20.65% |
| 2022 | CN¥2.01 Billion | -30.48% |
| 2021 | CN¥2.89 Billion | -6.68% |
| 2020 | CN¥3.10 Billion | +17.06% |
| 2019 | CN¥2.65 Billion | +53.02% |
| 2018 | CN¥1.73 Billion | -50.41% |
| 2017 | CN¥3.49 Billion | +46.41% |
| 2016 | CN¥2.38 Billion | -4.20% |
| 2015 | CN¥2.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Yifan Xinfu Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.37 Billion USD |
| MoneyControl | $2.37 Billion USD |
| MarketWatch | $2.37 Billion USD |
| marketcap.company | $2.37 Billion USD |
| Reuters | $2.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.